Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma

Background The peritumoral stroma is a hallmark of pancreatic ductal adenocarcinoma (PDA) with implications for disease development, progression and therapy resistance. We systematically investigated immune features of the stroma in PDA patients to identify markers of clinical importance and potential therapeutic targets. Methods Tissue and blood samples of 51 PDA patients with clinical and follow-up information were included. Laser Capture Microdissection allowed us to analyze the stromal compartment in particular. Systematic immunohistochemistry, followed by software-based image analysis were conducted. Also, multiplex cytokine analyses (including 50 immune-related molecules) were performed. Functional analyses were performed using patient-derived 3D bioprints. Clinical information was used for survival analyses. Intercompartmental IL9 and IL18 gradients were assessed in matched samples of tumor epithelium, stroma, and serum of patients. Serum levels were compared to an age-matched healthy control group. Results Stromal IL9 and IL18 are significantly associated with patient survival. While IL9 is a prognostic favorable marker (p=0.041), IL18 associates with poor patient outcomes (p=0.030). IL9 correlates with an anti-tumoral cytokine network which connects regulation of T helper (Th) 9, Th1 and Th17 cells (all: p<0.05 and r>0.5). IL18 correlates with a Th1-type cytokine phenotype and stromal CXCL12 expression (all: p<0.05 and r>0.5). Further, IL18 associates with a higher level of exhausted T cells. Inhibition of IL18 results in diminished Th1- and Th2-type cytokines. Patients with high stromal IL9 expression have a tumor-to-stroma IL9 gradient directed towards the stroma (p=0.019). Low IL18 expression associates with a tumor-to-stroma IL18 gradient away from the stroma (p=0.007). PDA patients showed higher serum levels of IL9 than healthy controls while serum IL18 levels were significantly lower than in healthy individuals. The stromal immune cell composition is distinct from the tumor epithelium. Stromal density of FoxP3+ regulatory T cells showed a tendency towards improved patient survival (p=0.071). Conclusion An unexpected high expression of the cytokines IL9 and IL18 at different ends is of significance in the stroma of PDA and relates to opposing patient outcomes. Sub-compartmental cytokine analyses highlight the importance of a differentiated gradient assessment. The findings suggest stromal IL9 and/or IL18 as markers for patient stratification and as potential therapeutic targets. Future steps include investigating e. g. the role of local microbiota as both cytokines are also regulated by microbial compositions.

[1]  N. Halama,et al.  Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma , 2022, Oncoimmunology.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  N. Halama,et al.  Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects , 2021, Journal for ImmunoTherapy of Cancer.

[4]  Y. S. Zhang,et al.  3D-bioprinted cancer-on-a-chip: level-up organotypic in vitro models. , 2021, Trends in biotechnology.

[5]  Yunmei Song,et al.  Three-Dimensional Printing for Cancer Applications: Research Landscape and Technologies , 2021, Pharmaceuticals.

[6]  B. Verrier,et al.  Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins , 2021, Frontiers in Immunology.

[7]  A. Chandrasekaran,et al.  A novel tumor-immune microenvironment (TIME)-on-Chip mimics three dimensional neutrophil-tumor dynamics and neutrophil extracellular traps (NETs)-mediated collective tumor invasion , 2021, Biofabrication.

[8]  N. Halama,et al.  Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma , 2021, Oncoimmunology.

[9]  N. Halama Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9 , 2020, British Journal of Cancer.

[10]  L. Apetoh Anticancer effects of the microbiota: how the microbiome shapes the development of IL-9-producing T cells , 2020, British Journal of Cancer.

[11]  N. Câmara,et al.  Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity , 2020, British Journal of Cancer.

[12]  G. Sukhikh,et al.  Macrophage Modification Strategies for Efficient Cell Therapy , 2020, Cells.

[13]  Ling-ling Sun,et al.  Th9 Cell Differentiation and Its Dual Effects in Tumor Development , 2020, Frontiers in Immunology.

[14]  R. Flavell,et al.  IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy , 2020, Nature.

[15]  M. Karamouzis,et al.  Immunotherapy for pancreatic cancer: A 2020 update. , 2020, Cancer treatment reviews.

[16]  Yong Lu,et al.  Targeting the IL-9 pathway in cancer immunotherapy , 2020, Human vaccines & immunotherapeutics.

[17]  Michelle A. Anderson,et al.  Regulatory T cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. , 2020, Cancer discovery.

[18]  J. D'haese,et al.  The role of interleukin-18 in pancreatitis and pancreatic cancer. , 2019, Cytokine & growth factor reviews.

[19]  Shanyu Qin,et al.  Targeted blockade of interleukin 9 inhibits tumor growth in murine model of pancreatic cancer. , 2019, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[20]  K. Nakanishi Unique Action of Interleukin-18 on T Cells and Other Immune Cells , 2018, Front. Immunol..

[21]  C. Denkert,et al.  Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. , 2017, European journal of cancer.

[22]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[23]  Bang-li Hu,et al.  Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis , 2017, BioMed research international.

[24]  R. Qin,et al.  Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer , 2016, Clinical Cancer Research.

[25]  M. Koch,et al.  Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. , 2016, Cancer cell.

[26]  I. Amit,et al.  Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling , 2015, Cell.

[27]  Zhiqiang Liu,et al.  Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells , 2015, Scientific Reports.

[28]  K. Xie,et al.  Pancreatic cancer stromal biology and therapy , 2015, Genes & diseases.

[29]  N. Murray,et al.  Complex role for the immune system in initiation and progression of pancreatic cancer. , 2014, World journal of gastroenterology.

[30]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[31]  Umar Mahmood,et al.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.

[32]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[33]  Yuhuan Zheng,et al.  Tumor-specific IL-9–producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers , 2014, Proceedings of the National Academy of Sciences.

[34]  Y. Miao,et al.  Role of CXCL12/CXCR4 signaling axis in pancreatic cancer , 2013, Chinese medical journal.

[35]  Mingli Yuan,et al.  Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion. , 2012, American journal of respiratory and critical care medicine.

[36]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[37]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[38]  Axel Benner,et al.  Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. , 2011, Cancer research.

[39]  M. Kloor,et al.  Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps. , 2010, Analytical and quantitative cytology and histology.

[40]  A. Singh,et al.  CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy , 2010, British Journal of Cancer.

[41]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[42]  Niels Grabe,et al.  Estimation of Immune Cell Densities in Immune Cell Conglomerates: An Approach for High-Throughput Quantification , 2009, PloS one.

[43]  C. Robino,et al.  IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival , 2009, Journal of immunotherapy.

[44]  J. Renauld,et al.  IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells , 2009, Proceedings of the National Academy of Sciences.

[45]  J. Kirkwood,et al.  A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma , 2009, Cancer.

[46]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. Koch,et al.  Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. , 2007, Arthritis and rheumatism.

[48]  Eun-Young Kim,et al.  Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model , 2007, BMC Cancer.

[49]  P. Allavena,et al.  Increased Survival, Proliferation, and Migration in Metastatic Human Pancreatic Tumor Cells Expressing Functional CXCR4 , 2004, Cancer Research.

[50]  M. Imamura,et al.  CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. , 2004, Molecular cancer therapeutics.

[51]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[52]  M. Eberl,et al.  IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen. , 2000, Vaccine.

[53]  L. Liotta,et al.  Laser Capture Microdissection , 1996, Science.